alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 626–650 of 2,047 studies published 2026 (page 26 of 82) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Burnout severity in residential dementia care: individual demands and institutional-level variation in a Hungarian cross-sectional study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BMC Nursing 2026-03-30

Caregiving difficulties showed excellent reliability (α = 0.928) and yielded three components explaining 73.19% of variance. 5 key findings →

Design: cross-sectional Participants: 1,254 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential associations of individual- and neighborhood-level socioeconomic status with mortality in dementia: Findings from the Mayo Clinic Study of Aging

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2026-09-03

BackgroundAlzheimer's disease (AD) and related dementias are leading causes of death worldwide. 4 key findings →

Participants: 6,909 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Comparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Clinical Neurology 2026-01-01

Fourteen participants (21.5%) converted to MCI, and 24 (36.9%) were classified as Prog-1.Plasma biomarkers did not show consistent predictive performance across predefined endpoints (all p>0.05), although NfL demonstrated modest discrimination for MCI conversion (area under the curve [AUC] 0.686, p=0.008).Hippocampal volume demonstrated significant discriminative performance for MCI conversion (AUC 0.765, p=0.016) and Prog-1 (AUC 0.933, p<0.001).For Prog-2, hippocampal volume showed high discrimination (AUC 0.952, p<0.001).WMH grade also demonstrated significant discrimination for MCI conversion (AUC 0.835, p<0.001) and Prog-1 (AUC 0.857, p<0.001).Bootstrap analyses (1,000 iterations) tended to show higher AUC estimates for imaging markers compared with plasma biomarkers. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mapping sex differences in brain and cognition in relation to APOE ε4 and amyloid burden: A longitudinal normative modelling study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2026-01-01

These findings highlight normative modelling's utility in revealing the complex interplay among sex, age, and AD risk in shaping brain structure and cognition in later life. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer’s related dementia severity classification from magnetic resonance imaging using derivative-free optimization of convolutional neural network

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2026-02-21

Magnetic resonance imaging based dementia severity assessment facilitates timely diagnosis of Alzheimer’s disease (AD) progression. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of Clinical and Translational Neurology 2026-01-28

These findings support the feasibility, tolerability, and high patient acceptability of pMRI. 3 key findings →

Participants: 130 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Family Caregiver Burden and Neuropsychiatric Symptoms in Japanese Community‐Dwelling People With Alzheimer's Disease: A Cross‐Sectional Study Using a Web‐Based Questionnaire

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Psychogeriatrics 2026-02-13

Family caregivers (n = 705) had a mean ± standard deviation (SD) age of 54.6 ± 11.5 years, 56.9% were male, and 84.0% cared for a parent or in-law with AD. 5 key findings →

Participants: 705 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Stigma, isolation, and depression in Chinese and Korean American dementia caregivers

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2026-04-01

These findings identify affiliate stigma as an important risk factor for dementia caregivers’ depressive symptoms, operating through both objective and emotional forms of social disconnection. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Community-engaged intervention mapping for developing the DIGNITY program: Supporting decision-making in aging and dementia for autonomy in rural nursing homes

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Clinical and Translational Science 2026-01-01

A total of 53 stakeholders participated in focus groups and engagement sessions. 5 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Application of Artificial Intelligence to Older Adults With Disabilities: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Applied Gerontology 2026-01-20

ObjectiveTo review the application of artificial intelligence (AI) in the care of older adults with disabilities, identifying intervention type, target populations, and effects. 5 key findings →

Participants: 15 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Gait and movement analysis for discrimination between people with dementia and healthy control persons based on pose estimation and machine learning

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2026-03-15

BackgroundDementia disorders are affecting millions of people globally, characterized by memory loss, communication difficulties, and motor function decline. 1 key finding →

Participants: 64 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The potential for dementia prevention in Japan: a population attributable fraction calculation for 14 modifiable risk factors and estimates of the impact of risk factor reductions

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Lancet Regional Health - Western Pacific 2026-01-01

The weighted combined PAF for all 14 risk factors was 38.9%, indicating that nearly 4 in 10 dementia cases in Japan might be preventable. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lewy Bodies Are Not Associated With Neuronal or Synaptic Loss in Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuropathology and Applied Neurobiology 2026-06-01

Across both regions, no evidence of reduced total neuronal density was observed, but a modest reduction in parvalbumin interneurons was observed in the cingulate gyrus, and there were only modest reductions in some synaptic markers in DLB. 4 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Altered temporal dynamics of prefrontal ERP responses reflecting neural adaptation in patients with amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s Research & Therapy 2026-01-07

Event-related potentials (ERPs), particularly the P200 component, have been studied as potential biomarkers, but conventional grand-averaged approaches often yield inconsistent results. 5 key findings →

Participants: 636 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Nonpharmacological multicomponent intervention for mild cognitive impairment with a family-patient approach: protocol for the pilot clinical trial—INTERCOG study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. PubMed Central 2026-06-01

Multicomponent and transdisciplinary interventions focused on the family member–patient dyad have the potential to optimize cognitive outcomes and quality of life. 1 key finding →

Participants: 40 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Streamlining eligibility assessment for Alzheimer's disease-modifying therapies: Prediction of MMSE scores using the digital clock and recall

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Digital Health 2026-07-09

The machine learning model predicted MMSE scores with a root-mean-squared error (RMSE) of 2.43 in the BH test set. 4 key findings →

Participants: 945 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

MMSE–CDR‐SB residual as an exploratory indicator of deviation from an Alzheimer's disease–typical cognitive–functional pattern

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2026-07-01

The MMSE–CDR‐SB residual may help flag less AD‐typical presentations for further etiologic evaluation, but cannot be interpreted as a pathology‐specific marker due to substantial overlap across diagnostic groups. 2 key findings →

Participants: 1,981 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Data-driven subtypes of type 2 diabetes and risk of dementia, stroke, and brain structural changes in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Diabetes Research and Clinical Practice 2026-05-08

Three subtypes emerged: severe obesity-related inflammatory diabetes (SOID), mild metabolic diabetes (MMD, reference), and mild age-related hypertension-predominant diabetes (MARD-H). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Imaging-genetics-based dementia risk prediction using deep survival neural networks in the Rotterdam Study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2026-04-09

Accurate dementia risk prediction is challenging, and may be facilitated by better use of imaging and genetic data, including their complex interactions. 1 key finding →

Design: post-hoc analysis Participants: 3,521 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Redox Biology 2026-03-10

Vascular cognitive impairment and dementia (VCID) is increasingly recognized as one of the leading causes of cognitive decline in aging populations. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglia-Derived Extracellular Vesicles from Alzheimer’s Disease Patients Carry miRNAs Driving a Neuroinflammatory Response

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular Neurobiology 2026-01-01

Alzheimer's disease (AD) represents the most common cause of dementia and urgently requires sensitive biomarkers and effective therapies. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed